Earnings
Elevance Health stock keeps guidance as Q3 earnings run ahead
Elevance Health has reiterated its 2026 adjusted EPS guidance of at least USD 27.00, despite third-quarter adjusted earnings tracking ahead of expectations. This continued guidance emphasizes the company's strong earnings execution and medical cost control. Elevance Health also reported Q2 adjusted EPS of USD 7.45, surpassing the consensus estimate, with the next earnings report scheduled for October 21, 2026.